RT Journal Article SR Electronic T1 Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 5773 OP 5782 DO 10.21873/anticanres.12916 VO 38 IS 10 A1 MATTEO SANTONI A1 FRANCESCO PIVA A1 UGO DE GIORGI A1 ALESSANDRA MOSCA A1 UMBERTO BASSO A1 DANIELE SANTINI A1 SEBASTIANO BUTI A1 CRISTIAN LOLLI A1 CARLO TERRONE A1 MARCO MARUZZO A1 MICHELE IULIANI A1 MELISSA BERSANELLI A1 ALESSANDRO CONTI A1 ROBERTA MAZZUCCHELLI A1 RODOLFO MONTIRONI A1 LUCIANO BURATTINI A1 ROSSANA BERARDI YR 2018 UL http://ar.iiarjournals.org/content/38/10/5773.abstract AB Background/Aim: Autophagy has been shown to be involved in cancer development and response to cancer therapy. In this study, genotypes of autophagic genes were analyzed to assess their correlation with the risk of clear cell renal cell carcinoma (ccRCC) and the outcome of patients treated with pazopanib for metastatic ccRCC. Materials and Methods: Single nucleotide polymorphisms (SNPs)were selected in the following genes: ATG4A (rs7880351), ATG4B (rs6709768), ATG4C (rs2886770, rs6670694, rs6683832), ATG5 (rs9373839, rs3804333, rs490010), ATG16L1 (rs6752107), ATG16L2 (rs10751215) and IRGM (rs10059011). The Kaplan–Meier method and log-rank test were used to evaluate differences between groups. Results: Forty patients with metastatic ccRCC treated with pazopanib were included in the analysis. ATG16L2rs10751215 was significantly less frequent in patients with ccRCC compared to the general population, suggesting its potential protective role, while ATG4Ars7880351, ATG4C rs6670694 and rs6683832 and ATG5 rs490010 were correlated with the progression-free survival (PFS) of patients treated with pazopanib. Conclusion: Our results suggest, for the first time, that autophagic gene SNPs are associated with ccRCC risk and patient outcome.